Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer
Relmada expects to initiate its Phase 3 program in the first half of 2026
Relmada expects to initiate its Phase 3 program in the first half of 2026
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
Subscribe To Our Newsletter & Stay Updated